PF-06281355 is a selective, orally active, mechanism-based myeloperoxidase (MPO) inhibitor, efficacious in cell assays and in vivo. Oral administration of PF-06281355 reduced plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Goodpasture disease, albuminuria and chronic renal dysfunction were completely suppressed by PF-06281355 treatment.

KEYWORDS: PF-06281355 | Supplier | MPO inhibitor | PF1355 | PF-1355 | PF 1355 | PF06281355 | PF 06281355 | CAS [1435467-38-1] | Hydrogen peroxide | Chloride | Myeloperoxidase | Inhibitor | Enzymes | Small vessel vasculitis